Introduction and Objective: The rising prevalence of obesity and related comorbidities highlights the need for safe, effective, and durable therapies. We evaluated PTT-A, a novel long-acting tetra-agonist targeting GLP-1, GIP, amylin, and calcitonin receptors, in diet-induced obese (DIO) rats and compared its efficacy with tirzepatide and CagriSema.Methods: DIO rats received PTT-A (10 or 30 nmol/kg), […]
Read MoreCategory: Diabetes
1282-OR: Major Adverse Limb Events with Tirzepatide vs. Injectable Semaglutide in Adults with Type 2 Diabetes and Peripheral Artery Disease
Introduction and Objective: Peripheral artery disease (PAD) increases the risk for amputations and limb-threatening events in people with type 2 diabetes (T2D). Tirzepatide and injectable semaglutide are associated with improved limb outcomes. However, real-world comparative outcomes are unknown.Methods: This retrospective cohort study used the TriNetX real-world global database across 112 healthcare organizations with over 130 […]
Read More1301-OR: Mitraa-T2D: Comparative Real-World Outcomes of a Digital Conversational Support Tool on Engagement, Adherence, and Glycemic Control in Adults with Type 2 Diabetes
Introduction and Objective: Limited patient engagement and suboptimal adherence remain major barriers in type 2 diabetes management. Digital conversational support tools may reinforce self-care between clinic visits. This study aimed to determine whether use of a digital conversational support tool, as an adjunct to usual care, is associated with improved behavioral and glycemic outcomes compared […]
Read More1305-OR: Emerging Type 1 Diabetes Screening and Intervention Programs: Insights from 63 Centers in the T1D Exchange Quality Improvement (Type 1 DiabetesX-QI) Collaborative
Introduction and Objective: Early stage T1D screening programs in routine clinical care are in their infancy. With the availability of teplizumab, a disease-modifying therapy that delays progression to Stage 3 T1D, there is an urgent need to reimagine T1D care. Understanding current screening practices can inform implementation strategies and identify gaps as the field moves […]
Read More1330-OR: Quantifying the Kinetics of Proglucagon-Derived Peptide Fragments Using Somatostatin and Glucagon Infusion
Introduction and Objective: Prohormone convertase enzymes within α-cells process proglucagon into several peptides. These include glicentin (GLY), major proglucagon fragment (MPGF), and oxyntomodulin (OXM). Assessing their in vivo secretion (SR) can provide insights on α-cell function in health and disease. However, estimating their SR from peripheral concentrations requires knowledge of their kinetics. Here we propose […]
Read More1283-OR: Feasibility and Acceptability of Deaf Diabetes Can Together (DEDICATE): A Diabetes Self-Management Education and Support Intervention in American Sign Language
Introduction and Objective: This pilot study aimed to examine feasibility and acceptability of a telehealth DSMES intervention, Deaf Diabetes Can Together (DEDICATE), to support Deaf and hard of hearing (DHH) adults with type 1 and type 2 diabetes.Methods: Diabetes DHH Participants completed a 10- to 12-week multicomponent telehealth intervention in ASL consisting of DSMES ASL […]
Read More1329-OR: Interlaboratory Validation and Method Comparison of a Novel LC-MS/MS Assay for Glucagon and Oxyntomodulin
Introduction and Objective: The quantification of plasma glucagon and oxytomodulin is important in the assessment of alpha-cell function, which is impaired in patients with diabetes. We aimed to develop, validate, and transfer between laboratories a novel assay that uses liquid chromatography-tandem mass spectrometry (LC-MS/MS) for the sensitive and specific measurement of these highly homologous hormones.Methods: […]
Read More1315-OR: Escaping Rejection: PD–L1/HVEM–Engineered β-Cells for Durable Transplant Survival
Introduction and Objective: Islet allo-transplantation can potentially cure type 1 diabetes (T1D), but immune rejection and systemic immunosuppression remain key challenges. Inspired by cancer immunotherapy, we hypothesized that engineering islet cells with checkpoint ligands could induce transplant tolerance. Our lab previously showed that autologous β cells reverse autoimmunity in NOD mice. Here, we demonstrate proof […]
Read More1320-OR: SPID-Engineered Long-Acting GIPR Antagonist Antibody for Weight Maintenance and Glycemic Recovery
Introduction and Objective: Obesity is a chronic disease requiring lifelong management, yet peptide agonists face high discontinuation and rebound weight gain due to dosing burdens. Improving therapeutic persistence requires long-acting agents optimized for weight maintenance. Leveraging antibody-based half-life extension, we developed a potent GIPR antagonist. This study evaluates its cellular potency and metabolic durability in […]
Read More1314-OR: Allogeneic Islets Are Rejected by Diabetic NOD Mice while Allogeneic Neo-Islets, 3D Organoids of Islet and Mesenchymal Stromal Cells, Durably Cure Their Type 1 Diabetes without Antirejection Drugs: Mechanisms
Introduction and Objective: T1D & T2D Dysglycemia impairs intrinsic Mesenchymal Stromal Cells’ (MSCs) protective & regenerative functions including those of pancreatic Islet-intrinsic MSCs. This accelerates b-Cell loss. Replacing MSCs at high numbers within Neo-Islets (NIs) corrects the dysfunction. The MSC component in NIs exerts trophic, anti-inflammatory, auto- and allo-immune modulatory actions (survival, angiogenic, anti-fibrotic). We […]
Read More